PDSB
NASDAQPDS Biotechnology Corporation
Price$1.14-0.04 (-3.39%)
01:30 PM07:45 PM
News · 26 weeks42+14%
2026-04-192026-10-11
Mix2590d
- SEC Filings15(60%)
- Other5(20%)
- Insider3(12%)
- Leadership2(8%)
Latest news
25 items- SECSEC Form S-3 filed by PDS Biotechnology CorporationS-3 - PDS Biotechnology Corp (0001472091) (Filer)
- SECSEC Form 8-K filed by PDS Biotechnology Corporation8-K - PDS Biotechnology Corp (0001472091) (Filer)
- PRPDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver MetastasesPRINCETON, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a virtual key opinion leader (KOL) event featuring Jonathan M. Hernandez, M.D, an Investigator with Surgical Oncology Program at the National Cancer Institute’s Center for Cancer Research. Dr. Hernandez will join company management to discuss clinical outcomes from the PDS0301 Phase 2 trials for the treatment of advanced liver-associated cancers, with a focus on the metastatic colorectal cancer (mCRC) cohort. The e
- SECPDS Biotechnology Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - PDS Biotechnology Corp (0001472091) (Filer)
- PRPDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor naïve patients Company continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC) while pursuing partnership strategy for PDS0101 PRINCETON, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the publication of results from a Phase 2 trial evaluating PDS0101, its HPV16-targeted immunotherapy, in combination with pembrolizumab in the September 17, 2026, issue of JAMA Oncology, a peer reviewed journa
- INSIDERSEC Form 3 filed by new insider Banaag Arnold James3 - PDS Biotechnology Corp (0001472091) (Issuer)
- INSIDERNew insider Soon-Shiong Patrick claimed ownership of 13,005,334 shares (SEC Form 3)3 - PDS Biotechnology Corp (0001472091) (Issuer)
- SECPDS Biotechnology Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - PDS Biotechnology Corp (0001472091) (Filer)
- INSIDERNew insider Trochimiuk Janetta claimed ownership of 1,124 shares (SEC Form 3)3 - PDS Biotechnology Corp (0001472091) (Issuer)
- SECPDS Biotechnology Corporation filed SEC Form 8-K: Termination of a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - PDS Biotechnology Corp (0001472091) (Filer)
- PRPDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of DirectorsGross Proceeds of $11.3 Million at Initial Closing Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks PRINCETON, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today announced the initial closing (the "Initial Closing") of the Company’s Private Investment in Public Equity ("PIPE") transaction. The round was led by Nant Capital, LLC ("Nant") with additional participation by current investors. The PIPE also consists of a contingent milestone closing (the "Milestone Closing") as described below. At the Initia
- SECPDS Biotechnology Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - PDS Biotechnology Corp (0001472091) (Filer)
- PRPDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorksDr. Soon-Shiong will Join PDS Biotech’s Board of Directors PDS Biotech Plans to Progress Development of PDS0301 Immunocytokine in Solid Tumors PRINCETON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today announced it has raised up to $22.55 million in equity funding in a Private Investment in Public Equity ("PIPE") transaction. The round was led by Nant Capital, LLC ("Nant") with additional participation by current investors. In connection with the PIPE, Nant will have the right to designate two members to join the Co
- SECPDS Biotechnology Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - PDS Biotechnology Corp (0001472091) (Filer)
- SECPDS Biotechnology Corporation filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update8-K - PDS Biotechnology Corp (0001472091) (Filer)
- SECPDS Biotechnology Corporation filed SEC Form 8-K: Leadership Update8-K - PDS Biotechnology Corp (0001472091) (Filer)
- SECPDS Biotechnology Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - PDS Biotechnology Corp (0001472091) (Filer)
- SECSEC Form 10-Q filed by PDS Biotechnology Corporation10-Q - PDS Biotechnology Corp (0001472091) (Filer)
- SECPDS Biotechnology Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PDS Biotechnology Corp (0001472091) (Filer)
- PRPDS Biotech Reports Second Quarter 2026 Financial ResultsPRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today provided a business and clinical programs update and reported financial results for the quarter ended June 30, 2026. Clinical and Corporate Update Announced publication of positive clinical and immunological biomarker data from Stage 1 of the NCI-led metastatic colorectal cancer (mCRC) Phase 2, open-label, single-center, non-randomized clinical trial evaluating PDS0301 (formerly PDS01ADC), the Company’s tumor-targeted IL-12 immunocytokine. The clinical trial
- SECPDS Biotechnology Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - PDS Biotechnology Corp (0001472091) (Filer)
- PRPDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101PRINCETON, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on developing targeted immunotherapies for cancer, today issued a Letter to Shareholders from Frank Bedu-Addo, Ph.D., Chief Executive Officer and Director of PDS Biotech: "Dear Fellow Shareholders, Over the past several months, our Board of Directors and management team conducted a comprehensive review of our development portfolio, capital allocation priorities and long-term strategy. Following this review, we believe the best path to creating long-term shareholder value is to prioritize the advancement of PDS0301, our
- SECPDS Biotechnology Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - PDS Biotechnology Corp (0001472091) (Filer)
- SECSEC Form EFFECT filed by PDS Biotechnology CorporationEFFECT - PDS Biotechnology Corp (0001472091) (Filer)
- SECSEC Form 424B4 filed by PDS Biotechnology Corporation424B4 - PDS Biotechnology Corp (0001472091) (Filer)
PDSB FAQ
7 questionsWhat does PDS Biotechnology Corporation do?
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1)...Where does PDSB stock trade?
PDS Biotechnology Corporation (PDSB) is listed on NASDAQ.What sector and industry is PDSB in?
PDS Biotechnology Corporation operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did PDS Biotechnology Corporation go public?
PDS Biotechnology Corporation (PDSB) completed its IPO in 2015.What are analysts saying about PDSB?
PDS Biotechnology Corporation has had 3 recent analyst actions on file. The most recent action was from B. Riley Securities: Buy with a $1000.00 price target on 2022-11-01. Recent price targets range from $1000.00 to $2500.00.What companies are similar to PDSB?
Notable peers in the same industry include IOBT (IO Biotech Inc.), SQZ (SQZ Biotechnologies Company), EDSA (Edesa Biotech Inc.), BBI (Brickell Biotech Inc.). Compare PDSB side-by-side with any of them on Quantisnow.How can I track PDSB on Quantisnow?
Quantisnow aggregates PDS Biotechnology Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PDSB to receive live email and push alerts on every new disclosure.